Trial reportHIV clinical trials2017
Virologic outcomes in early antiretroviral treatment: HPTN 052.
Trial report in HIV clinical trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review.BMC public health · 2021Pooled it
- Rapid initiation of antiretroviral therapy for people living with HIV.The Cochrane database of systematic reviews · 2019Pooled it
- An autoregressive cross-lagged model unraveling co-occurring stimulant use and HIV: Results from a randomized controlled trial.Drug and alcohol dependence · 2021Trial
- Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052.PloS one · 2017Trial
- Interventions for thriving in HIV serodiscordant relationships in Sub-Saharan Africa: a scoping review.BMC public health · 2026Article
- Characteristics of Drug Resistance Mutations in a Korean HIV/AIDS Cohort, and Risk Factors for Resistance Acquisition in ART-Experienced Patients.Infection & chemotherapy · 2026Article
- Prevalence of virological failure and associated factors among adult individuals on highly active antiretroviral treatment (HAART) in public health facilities at Tulu Bolo Town, Southwest Shoa, Ethiopia, 2024.Frontiers in public health · 2025Article
- Time from treatment initiation to HIV viral suppression in public care facilities in Brazil: A nationwide linked databases cohort.PloS one · 2024Article
- Rapid antiretroviral therapy and treatment outcomes among people living with HIV: exploring the mediating roles of medication adherence.Frontiers in public health · 2024Article
- Combination HIV prevention during pregnancy and the post-partum period in Malawi and Zambia: a mathematical modelling analysis.Journal of the International AIDS Society · 2023Article
- Machine learning to predict virological failure among HIV patients on antiretroviral therapy in the University of Gondar Comprehensive and Specialized Hospital, in Amhara Region, Ethiopia, 2022.BMC medical informatics and decision making · 2023Article
- Association between social support and viral load in adults on highly active antiretroviral therapy - Witbank, South Africa.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2020Article
- Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention.PLoS computational biology · 2020Article
- Genital Shedding of Human Immunodeficiency Virus Type-1 (HIV) When Antiretroviral Therapy Suppresses HIV Replication in the Plasma.The Journal of infectious diseases · 2020Article
- Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study.Pathogens & immunity · 2020Article
- Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.Antimicrobial agents and chemotherapy · 2019Article
- Results of Early Virologic Monitoring May Facilitate Differentiated Care Monitoring Strategies for Clients on ART, Rakai, Uganda.Open forum infectious diseases · 2018Article
- Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa.International journal of STD & AIDS · 2018Observational
- HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052.Journal of acquired immune deficiency syndromes (1999) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 17 institutions in 9 countries.
Funding
Abstract
introductionThe HIV Prevention Trials Network (HPTN) 052 trial demonstrated that early antiretroviral therapy (ART) prevented 93% of HIV transmission events in serodiscordant couples. Some linked infections were observed shortly after ART initiation or after virologic failure.
objectiveTo evaluate factors associated with time to viral suppression and virologic failure in participants who initiated ART in HPTN 052.
methods1566 participants who had a viral load (VL) > 400 copies/mL at enrollment were included in the analyses. This included 832 in the early ART arm (CD4 350-550 cells/mm
resultsOverall, 93% of participants achieved viral suppression by 12 months. The annual incidence of virologic failure was 3.6%. Virologic outcomes were similar in the two study arms. Longer time to viral suppression was associated with younger age, higher VL at ART initiation, and region (Africa vs. Asia). Virologic failure was strongly associated with younger age, lower educational level, and lack of suppression by three months; lower VL and higher CD4 at ART initiation were also associated with virologic failure.
conclusionsSeveral clinical and demographic factors were identified that were associated with longer time to viral suppression and virologic failure. Recognition of these factors may help optimize ART for HIV treatment and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.